Late luteal administration of the antiprogesterone RU486 in normal women: effects on the menstrual cycle events and fertility control in a long-term study.
Twelve regularly cycling women, with contraindications to other methods of contraception, received RU486 (Roussel UCLAF, Romainville, France), once a month as a method of fertility control. The study was designed for 18 consecutive cycles. Each patient recorded basal body temperature, detected urinary luteinizing hormone peak, and collected saliva samples during each luteal phase for progesterone (P) determinations. A single dose of RU486, 600 mg, was given on the day before the expected date of the menses and 8 days later in case of continuing pregnancy after the first dose. Blood samples were collected for estradiol, P, and beta-human chorionic gonadotropin analyses on these two occasions. The compliance was poor and the results of only 137 cycles were obtained. The menstrual cyclicity was not significantly modified during this long-term study. Of the 137 cycles, 22 pregnancies occurred (16%), and 4 (18.2%) were not interrupted by the second dose of RU486. Thus, because of the high failure rate, use of RU486 at the time of the natural P withdrawal cannot be advocated as a "once-a-month" contragestive agent.
Couzinet
B
B
Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
Le Strat
N
N
Silvestre
L
L
Schaison
G
G
D000328:Adult; D004702:Endocrine Glands / Q000187:drug effects; D005193:Family Planning Services / Q000379:methods*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008183:Luteal Phase; D008597:Menstrual Cycle / Q000187:drug effects*; D015735:Mifepristone / Q000009:adverse effects / Q000494:pharmacology*; D011247:Pregnancy / Q000187:drug effects; D011374:Progesterone / Q000037:antagonists & inhibitors; D012016:Reference Values; D013997:Time Factors
D015735:Mifepristone; D011374:Progesterone